Skip to main content
Chronic Diseases and Translational Medicine logoLink to Chronic Diseases and Translational Medicine
. 2018 Jun 11;4(2):135–138. doi: 10.1016/j.cdtm.2018.05.002

Maxwell's demon at work: Mitochondria, the organelles that convert information into energy?

Ya Wen a,b,
PMCID: PMC6034008  PMID: 29988942

Mitochondria (singular, mitochondrion) are important organelles that in the center of energy production and information processing. They are primarily known as the powerhouse of the cell, as they produce most of the energy that cells need for all kinds of activities. This is done by generating the cellular energy currency, adenosine triphosphate (ATP). In addition to energy production, mitochondria play a central role in regulating signal transduction as signaling organelles. Mitochondria control Ca2+ homeostasis, reactive oxygen species (ROS) generation and elimination, cellular differentiation, and programmed cell death (apoptosis). They are involved in many signaling pathways including calcium, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)-Akt, mammalian target of rapamycin (mTOR), wingless-int (Wnt), Ras, and insulin signaling pathways. There are accumulating evidences that suggest mitochondrial dysfunction is associated with a variety of diseases and aging. Mitochondria have been extensively researched in many areas. This article is not intent to provide a comprehensive review of each area of study, but rather to propose a hypothesis of information-energy conversion as a new viewpoint for future research.

Mitochondria: energy production

Mitochondria use oxygen within the cells and generate energy by metabolizing fuel molecules such as pyruvate from glucose and fatty acids from fats, through respiration.1 The process is called oxidative phosphorylation in which ATP is formed as a result of the transfer of electrons from nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) to O2, forming H2O.2 The oxidative phosphorylation requires an electrochemical proton gradient across the inner mitochondrial membrane, with three procedures occurring at the same time: electron transport, proton pumping, and ATP formation. The process is conducted by the respiratory chain (RC) complexes (Complex I, Complex II, Complex III, and Complex IV) and ATP synthase (Complex V) located in the inner mitochondrial membrane. Energy released by the electron transfer from NADH and FADH2 to O2 is used to pump protons (H+) via Complex I, Complex III, and Complex IV. The proton gradient across the inner mitochondrial membrane drives ATP production via ATP synthase.3 This process requires intact mitochondrial membrane for the proton concentration gradient and electric potential. Otherwise the oxidation may still occurs but no ATP is produced.4

Mitochondria: cell signaling

Oxidative phosphorylation generates reactive oxygen species (ROS) as byproducts. ROS are chemically reactive chemical species containing oxygen such as peroxides, superoxide, hydroxyl radical, and singlet oxygen. Excessive amount of intracellular levels of ROS will cause oxidative damage to components of the cell, including nucleic acids (DNA, RNA), proteins, and lipids.5 Cells control ROS levels by balancing the generation of ROS with their elimination by a variety of antioxidant enzymes that convert ROS into less harmful forms. However, if the conversion is less efficient, or there is a dramatically increase of the levels of ROS, cells would undergo oxidative stress – the condition caused by the imbalance between the production of ROS and antioxidant defenses.6 Oxidative stress is associated with a range of diseases such as cancer, diabetes, autism, attention deficit hyperactivity disorder (ADHD), Parkinson's disease, Alzheimer's disease, depression, heart failure, and chronic fatigue syndrome.7, 8, 9, 10, 11

On the other hand, ROS have important roles in cell signaling. ROS serve as critical signaling molecules in cell proliferation and survival. While excess ROS induce oxidative damage and promote cell death, at normal levels (amounts), ROS function as “redox (reduction–oxidation reaction) messengers” in intracellular signaling and regulation. ROS regulate several signaling pathways through interaction with critical signaling molecules, affecting a variety of cellular processes, such as proliferation, metabolism, differentiation, and survival.6, 12, 13, 14 These signaling pathways include MAPK signaling, Ras signaling, PI3K-Akt Signaling, calcium signaling, etc.13 Disturbances of ROS-dependent cell signaling will affect the complicated signaling pathway network and trigger a range of conditions.

Mitochondria: cell death

If there are too much damages present in mitochondria, a cell undergoes apoptosis. Apoptosis is a naturally occurring programmed process that eliminate cells by activating caspases (aspartate-specific cysteine proteases, they are enzymes that degrade proteins). B-cell lymphoma 2 (Bcl-2) family of proteins are localized to the outer and inner membrane of mitochondria, and regulate the apoptosis as an important gatekeeper. The Bcl-2 family consists of anti-apoptotic members such as Bcl-2 and pro-apoptotic members such as Bcl-2 associated X (Bax) and Bcl-2 homologous antagonist killer (Bak). Once activated, the proteins Bax and Bak will promote mitochondrial outer membrane permeabilization (MOMP) which leads to the release of cytochrome C. Cytochrome C binds to apoptotic protease activating factor-1 (Apaf-1) and form apoptosomes which activate caspase-9. The caspase-9 then initiates the caspase cascade, a chain reaction of protein degradation and eventually cell death.15, 16 On the other hand, by binding to Bax and Bak, anti-apoptotic protein Bcl-2 inhibits the MOMP thus prevents the apoptosis. The behavior of the Bcl-2 proteins depends on the pro-apoptotic and anti-apoptotic signals. By responding to these signals, the Bcl-2 family of proteins act as a cell life and death decision maker. Therefore, it is the balance between the pro-apoptotic and anti-apoptotic signals that eventually determines whether cells will undergo apoptosis, survive or proliferate.

Apoptosis is vital to various biological activities including embryogenesis, development, functioning of the immune system, and aging. Apoptosis imbalance (too little or too much cell death) will trigger a variety of diseases including cancer, neurodegenerative diseases, and autoimmune disorders.17, 18, 19 By controlling apoptosis, mitochondria not only play a key role in eliminating damaged cells, but also in development. Proper mitochondrial functioning is important to health.

Mitochondrial dysfunction: a key player in chronic diseases?

Mitochondria are found in every cell of the human body except red blood cells. Therefore, it is not surprising to see that loss of function in mitochondria, or mitochondrial dysfunction, would result in numerous conditions throughout the whole body. These conditions cross the timeframe from birth to death, including: poor growth, developmental delays,20 learning disabilities,21 muscle weakness, excess fatigue, exercise intolerance,22 nervous system dysfunction,23, 24 neurological problems,25 neurodevelopment disorders,26 neurodegenerative disorders,27 visual problems, hearing problems,28 gastrointestinal disorders,29 respiratory disorders,30 metabolic disorders,31 heart diseases,32 liver diseases,33 kidney diseases,34 and cancer.35 Many of these conditions are in the category of “chronic diseases (or conditions)” that are the ones lasting for 3 months or more. Chronic diseases constitute a major cause of mortality, and have a great deal of impact on the quality of life. Mitochondrial dysfunction is directly or indirectly related to almost all chronic diseases due to the mitochondrial functions of energy production and cell signaling. Disturbances in these two functions would cause a series of consequences throughout life. The outcomes depend on many factors and may vary greatly in presentation from different people, at different times, and in different environment. If malfunction of mitochondria is the core of all chronic diseases/conditions, it would make a lot of sense to develop strategies around mitochondrial function for effective disease prevention and treatments.

Maxwell's demon – mitochondria convert information into energy?

Base on the discussion above, mitochondria are vital to human health and are in the control of cell life and death that depend on energy production and information processing (signal transduction and such). Energy and information, they are two most important things to every living being. Mitochondria are in the center of these two things in cells.

We know that energy and matter are interchangeable, and in a way they are just different aspects of the same thing. There are many different forms of energy such as electrical, thermal, nuclear, electromagnetic, chemical, and sound. Energy can be transformed from one form to another. How about energy and information? Is information also a form of energy? Are they interchangeable? If so, are mitochondria actually converting/transforming information into energy?

“Maxwell's demon” is a thought experiment that convert information into energy, which was created by the physicist James Clerk Maxwell in 1867. In the thought experiment, Maxwell proposed a vessel that was divided into two portions, A and B, by a door. The vessel contains gas in which some molecules are faster (hotter) and some are cooler (slower). A demon (a hypothetical being) controls the door and allows only faster molecules pass through the door from A to B and slower molecules from B to A, whenever the individual molecules approach the door. The result is that all the hot molecules end up in B and cool molecules in A. Thus the demon creates a temperature difference from processing the information of the gas molecule temperatures.36 The demon has essentially converted a disordered state (randomness, higher entropy) to ordered state (order, lower entropy), thus decreased entropy.

Is mitochondrion the Maxwell's demon at work in nature? The idea is that mitochondria produce energy from information processing, or rather, convert information into energy. By doing that, mitochondria support the living system of human beings.

Living systems use information and energy to maintain highly-ordered state and stable entropy.37 An interesting study by Frieden and Gatenby, proposed that “the evolution of a normal cell into a cancer cell represents an information phase transition from a maximum to a minimum value”, probably begins with loss of energy, and possibly involves mitochondrial dysfunction.38 It is possible that change of the state of the information could affect the state of energy, and vice versa. The information-energy imbalance could be the fundamental cause of diseases.

If we considered that the information and energy were two different aspects of the same thing, then they should be interchangeable. Therefore, the information-energy imbalance could be corrected. And we would be able to treat all kinds of diseases by fixing the imbalance with the interchangeable information and energy.

Future

If this hypothesis is true, there would be endless potential implications of the theory of information-energy conversion. For example, energy-information medicine, environmental medicine, light and frequency therapy, effective disease prevention (detect disease before it happens) – detect the abnormal energy-information interchange…

Mitochondria provide an excellent model for us to learn about information-energy relationship. Development of the theory of information-energy conversion will open a new era in biology – theoretical biology which requires teamwork from biologists and physicists.

Conflicts of interest

The author declares that she has no conflicts of interest.

Edited by Yang Pan

Footnotes

Peer review under responsibility of Chinese Medical Association.

References

  • 1.Alberts B., Johnson A., Lewis J. Molecular Biology of the Cell. 4th ed. Garland Science; New York: 2002. The mitochondrion. [Google Scholar]
  • 2.Berg J.M., Tymoczko J.L., Stryer L. Biochemistry. 5th ed. W.H.Freeman; New York: 2002. Oxidative phosphorylation. [Google Scholar]
  • 3.Berg J.M., Tymoczko J.L., Stryer L. Biochemistry. 5th ed. W.H.Freeman; New York: 2002. The respiratory chain consists of four complexes: three proton pumps and a physical link to the citric acid cycle. [Google Scholar]
  • 4.Lodish H., Berk A., Zipursky S.L. Molecular Cell Biology. 4th ed. W. H. Freeman; New York: 2000. Electron transport and oxidative phosphorylation. [Google Scholar]
  • 5.Birben E., Sahiner U.M., Sackesen C., Erzurum S., Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5:9–19. doi: 10.1097/WOX.0b013e3182439613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Schieber M., Chandel N.S. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24:R453–R462. doi: 10.1016/j.cub.2014.03.034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pham-Huy L.A., He H., Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomed Sci. 2008;4:89–96. [PMC free article] [PubMed] [Google Scholar]
  • 8.Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology. 2006;13:171–181. doi: 10.1016/j.pathophys.2006.05.007. [DOI] [PubMed] [Google Scholar]
  • 9.Uttara B., Singh A.V., Zamboni P., Mahajan R.T. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol. 2009;7:65–74. doi: 10.2174/157015909787602823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Jammes Y., Steinberg J.G., Mambrini O., Brégeon F., Delliaux S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med. 2005;257:299–310. doi: 10.1111/j.1365-2796.2005.01452.x. [DOI] [PubMed] [Google Scholar]
  • 11.Joseph N., Zhang-James Y., Perl A., Faraone S.V. Oxidative stress and ADHD: a meta-analysis. J Atten Disord. 2015;19:915–924. doi: 10.1177/1087054713510354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Reczek C.R., Chandel N.S. ROS-dependent signal transduction. Curr Opin Cell Biol. 2015;33:8–13. doi: 10.1016/j.ceb.2014.09.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Zhang J., Wang X., Vikash V. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev. 2016;2016:4350965. doi: 10.1155/2016/4350965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Finkel T. Signal transduction by reactive oxygen species. J Cell Biol. 2011;194:7–15. doi: 10.1083/jcb.201102095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Willis S., Day C.L., Hinds M.G., Huang D.C. The Bcl-2-regulated apoptotic pathway. J Cell Sci. 2003;116:4053–4056. doi: 10.1242/jcs.00754. [DOI] [PubMed] [Google Scholar]
  • 16.Tsujimoto Y. Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria? Genes Cells. 1998;3:697–707. doi: 10.1046/j.1365-2443.1998.00223.x. [DOI] [PubMed] [Google Scholar]
  • 17.Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516. doi: 10.1080/01926230701320337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Renehan A.G., Booth C., Potten C.S. What is apoptosis, and why is it important? BMJ. 2001;322:1536–1538. doi: 10.1136/bmj.322.7301.1536. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Favaloro B., Allocati N., Graziano V., Di Ilio C., De Laurenzi V. Role of apoptosis in disease. Aging (Albany NY) 2012;4:330–349. doi: 10.18632/aging.100459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Fillano J.J., Goldenthal M.J., Rhodes C.H., Marín-García J. Mitochondrial dysfunction in patients with hypotonia, epilepsy, autism, and developmental delay: HEADD syndrome. J Child Neurol. 2002;17:435–439. doi: 10.1177/088307380201700607. [DOI] [PubMed] [Google Scholar]
  • 21.Koenig M.K. Presentation and diagnosis of mitochondrial disorders in children. Pediatr Neurol. 2008;38:305–313. doi: 10.1016/j.pediatrneurol.2007.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Filler K., Lyon D., Bennett J. Association of mitochondrial dysfunction and fatigue: a review of the literature. BBA Clin. 2014;1:12–23. doi: 10.1016/j.bbacli.2014.04.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Finsterer J. Treatment of central nervous system manifestations in mitochondrial disorders. Eur J Neurol. 2011;18:28–38. doi: 10.1111/j.1468-1331.2010.03086.x. [DOI] [PubMed] [Google Scholar]
  • 24.DiMauro S., Schon E.A. Mitochondrial disorders in the nervous system. Annu Rev Neurosci. 2008;31:91–123. doi: 10.1146/annurev.neuro.30.051606.094302. [DOI] [PubMed] [Google Scholar]
  • 25.Parikh S. The neurologic manifestations of mitochondrial disease. Dev Disabil Res Rev. 2010;16:120–128. doi: 10.1002/ddrr.110. [DOI] [PubMed] [Google Scholar]
  • 26.Falk M.J. Neurodevelopmental manifestations of mitochondrial disease. J Dev Behav Pediatr. 2010;31:610–621. doi: 10.1097/DBP.0b013e3181ef42c1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Reddy P.H. Role of mitochondria in neurodegenerative diseases: mitochondria as a therapeutic target in Alzheimer's disease. CNS Spectr. 2009;14:8–13. doi: 10.1017/s1092852900024901. discussion 16–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Fraser J.A., Biousse V., Newman N.J. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol. 2010;55:299–334. doi: 10.1016/j.survophthal.2009.10.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Finsterer J., Frank M. Gastrointestinal manifestations of mitochondrial disorders: a systematic review. Therap Adv Gastroenterol. 2017;10:142–154. doi: 10.1177/1756283X16666806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Berardo A., Musumeci O., Toscano A. Cardiological manifestations of mitochondrial respiratory chain disorders. Acta Myol. 2011;30:9–15. [PMC free article] [PubMed] [Google Scholar]
  • 31.McInnes J. Mitochondrial-associated metabolic disorders: foundations, pathologies and recent progress. Nutr Metab (Lond) 2013;10:63. doi: 10.1186/1743-7075-10-63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rosca M.G., Hoppel C.L. Mitochondrial dysfunction in heart failure. Heart Fail Rev. 2013;18:607–622. doi: 10.1007/s10741-012-9340-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Grattagliano I., Russmann S., Diogo C. Mitochondria in chronic liver disease. Curr Drug Targets. 2011;12:879–893. doi: 10.2174/138945011795528877. [DOI] [PubMed] [Google Scholar]
  • 34.Che R., Yuan Y., Huang S., Zhang A. Mitochondrial dysfunction in the pathophysiology of renal diseases. Am J Physiol Renal Physiol. 2014;306:F367–F378. doi: 10.1152/ajprenal.00571.2013. [DOI] [PubMed] [Google Scholar]
  • 35.Wallace D.C. Mitochondria and cancer. Nat Rev Cancer. 2012;12:685–698. doi: 10.1038/nrc3365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Knott C.G. Cambridge University Press; Cambridge: 1911. Life and Scientific Work of Peter Guthrie Tait, Supplementing the Two Volumes of Scientific Papers Published in 1898 and 1900. [Google Scholar]
  • 37.Gatenby R.A., Frieden B.R. Information theory in living systems, methods, applications, and challenges. Bull Math Biol. 2007;69:635–657. doi: 10.1007/s11538-006-9141-5. [DOI] [PubMed] [Google Scholar]
  • 38.Frieden B.R., Gatenby R.A. Information dynamics in living systems: prokaryotes, eukaryotes, and cancer. PLoS One. 2011;6:e22085. doi: 10.1371/journal.pone.0022085. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Chronic Diseases and Translational Medicine are provided here courtesy of Chinese Medical Association

RESOURCES